Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.

Julia Hippisley-CoxDuncan YoungCarol CouplandKeith M ChannonPui San TanDavid A HarrisonKathryn RowanPaul AveyardIan D PavordPeter J Watkinson

Published in: Heart (British Cardiac Society) (2020)

ACE inhibitors and ARBs are associated with reduced risks of COVID-19 disease after adjusting for a wide range of variables. Neither ACE inhibitors nor ARBs are associated with significantly increased risks of receiving ICU care. Variations between different ethnic groups raise the possibility of ethnic-specific effects of ACE inhibitors/ARBs on COVID-19 disease susceptibility and severity which deserves further study.

Keyphrases

angiotensin converting enzyme
coronavirus disease
angiotensin ii
sars cov
healthcare
intensive care unit
human health
risk assessment
respiratory syndrome coronavirus
pain management
health insurance